Abstract
Radioimmunoguided surgery (RIGS) was developed to improve on the intraoperative detection of malignancy. The RIGS system uses a hand-held gamma radiation detection probe to identify radioactive tissues targeted by a preadministered tumor-associated radiolabeled targeting antibody or peptide. Clinical experience with RIGS in colorectal cancer has been favorable; better intraoperative staging has provided the surgeon more information regarding the pattern of disease and individual patients. Pancreatic, breast, ovarian, and prostate cancer have also been studied in clinical trials using RIGS and early results are encouraging. In the future, marked improvements with the RIGS system will be realized with the development of better targeting agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
